Riverview Trust Co Cuts Stake in Becton, Dickinson and Company (NYSE:BDX)

Riverview Trust Co cut its stake in Becton, Dickinson and Company (NYSE:BDX) by 3.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,215 shares of the medical instruments supplier’s stock after selling 42 shares during the period. Riverview Trust Co’s holdings in Becton, Dickinson and Company were worth $293,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Perpetual Ltd purchased a new stake in Becton, Dickinson and Company in the 1st quarter valued at $221,000. Wedmont Private Capital purchased a new position in Becton, Dickinson and Company during the first quarter worth about $227,000. Marcum Wealth LLC boosted its holdings in Becton, Dickinson and Company by 4.8% in the 1st quarter. Marcum Wealth LLC now owns 1,156 shares of the medical instruments supplier’s stock valued at $286,000 after purchasing an additional 53 shares in the last quarter. Gulf International Bank UK Ltd increased its position in Becton, Dickinson and Company by 0.6% during the 1st quarter. Gulf International Bank UK Ltd now owns 25,075 shares of the medical instruments supplier’s stock worth $6,204,000 after purchasing an additional 159 shares during the period. Finally, &PARTNERS acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $711,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Evercore ISI upped their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Stifel Nicolaus upped their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Raymond James dropped their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $243.75 on Friday. The business has a fifty day simple moving average of $237.01 and a 200-day simple moving average of $235.28. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $262.23. The company has a market cap of $70.45 billion, a P/E ratio of 53.69, a P/E/G ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. During the same period in the previous year, the firm earned $2.96 earnings per share. Becton, Dickinson and Company’s revenue was up 2.3% compared to the same quarter last year. Equities research analysts forecast that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were given a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.56%. The ex-dividend date was Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.